Schenck M, Luetzke A, Ruebben H, Schneider T
Urologische Universitätsklinik, Essen.
Aktuelle Urol. 2011 Jan;42(1):38-45. doi: 10.1055/s-0030-1262748. Epub 2011 Jan 25.
A standard protocol for perioperative antibiotic prophylaxis in radical retropubic prostatectomy has not been established until now. The present pilot study compared the perioperative single-dose of piperacillin/tazobactam to the administration of ciprofloxacin or cotrimoxazol for 5 days with regard to postoperative infections. For the first time these antibiotic regimes were described in radical retropubic prostatectomy.
The patients were divided into three groups, each consisting of 17 patients: group 1: a single-dose of piperacillin / tazobactam 4.5 g i. v., group 2: ciprofloxacin 500 mg or cotrimoxazol 960 mg i. v. / p. o. and group 3: varying administration and duration of different kinds of antibiotics as control group. The basic characteristics of the patients such as age, body-mass-index, risk factors, diseases, former surgeries and medication were similar between all three groups. Also there were no significant differences in intraoperative parameters such as operation time, blood loss and other postoperative complications.
The piperacillin / tazobactam group showed a significantly lower body temperature on postoperative days (POD) 1-3. The laboratory values were not significantly different among the groups, except the piperacillin / tazobactam group showed a significantly lower CRP level on POD 1-3 than group 3. All antibiotic regimes could afford an efficient protection: None of the patients died and there were no cases of serious consequences such as pneumonia, urosepsis or bacteriuria. Although not statistically significant, the piperacillin / tazobactam group showed better clinical outcomes: here the length of hospitalisation was two days less than in the other groups, no cases of wound infection occurred, the antimicrobial resistance rates were lower and fewer patients were treated with antibiotics in the postoperative course.
Comparable to similar studies with a larger number of patients our pilot study demonstrated, although statistically not significant, better clinical results overall. We therefore conclude that a single-dose of piperacillin / tazobactam appears to be an efficient antibiotic prophylaxis in radical retropubic prostatectomy and even in some clinical parameters piperacillin / tazobactam seems to be equivalent or better than the usual 5-day administration of antimicrobial prophylaxis.
迄今为止,耻骨后根治性前列腺切除术围手术期抗生素预防的标准方案尚未确立。本初步研究比较了围手术期单剂量哌拉西林/他唑巴坦与环丙沙星或复方新诺明连用5天对术后感染的影响。这些抗生素治疗方案在耻骨后根治性前列腺切除术中的应用首次得到描述。
患者分为三组,每组17例:第1组:静脉注射单剂量4.5g哌拉西林/他唑巴坦;第2组:静脉注射/口服500mg环丙沙星或960mg复方新诺明;第3组:作为对照组,使用不同种类抗生素,给药方式和持续时间各异。三组患者的基本特征,如年龄、体重指数、危险因素、疾病、既往手术史和用药情况相似。术中参数,如手术时间、失血量和其他术后并发症也无显著差异。
哌拉西林/他唑巴坦组在术后第1 - 3天体温显著较低。除哌拉西林/他唑巴坦组在术后第1 - 3天的CRP水平显著低于第3组外,各组实验室值无显著差异。所有抗生素治疗方案均能提供有效保护:无患者死亡,无肺炎、尿脓毒症或菌尿症等严重后果病例。尽管无统计学意义,但哌拉西林/他唑巴坦组临床结果更佳:住院时间比其他组少两天,无伤口感染病例,抗菌耐药率较低,术后使用抗生素治疗的患者较少。
与大量患者的类似研究相比,我们的初步研究表明,尽管无统计学意义,但总体临床结果更好。因此,我们得出结论,单剂量哌拉西林/他唑巴坦似乎是耻骨后根治性前列腺切除术有效的抗生素预防用药,甚至在某些临床参数方面,哌拉西林/他唑巴坦似乎等同于或优于通常的5天抗菌预防用药。